Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) EBITDA Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed EBITDA Margin for 6 consecutive years, with 37.02% as the latest value for Q4 2023.

  • On a quarterly basis, EBITDA Margin rose 40740211.0% to 37.02% in Q4 2023 year-over-year; TTM through Sep 2024 was 131.96%, a 14133.0% increase, with the full-year FY2023 number at 41.66%, up 968106.0% from a year prior.
  • EBITDA Margin was 37.02% for Q4 2023 at Denali Therapeutics, up from 7779.24% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 3689.18% in Q2 2023 to a low of 407439.13% in Q4 2022.
  • A 5-year average of 36604.36% and a median of 624.57% in 2020 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -40682191bps in 2022, then surged 40740211bps in 2023.
  • Denali Therapeutics' EBITDA Margin stood at 205.53% in 2019, then plummeted by -538bps to 1311.47% in 2020, then soared by 53bps to 617.22% in 2021, then plummeted by -65912bps to 407439.13% in 2022, then skyrocketed by 100bps to 37.02% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's EBITDA Margin are 37.02% (Q4 2023), 7779.24% (Q3 2023), and 3689.18% (Q2 2023).